Eiffel to focus on developing inhaled and transdermal insulin
Wednesday, 31 March, 2004
Eiffel Technologies (ASX : EIF) announced today it has completed further animal studies in its development of improved injectable insulin, and would focus resources on collaborations with pharmaceutical companies working on inhaled or transdermal insulin.
The studies confirmed that Eiffels re-engineered insulin is at least equivalent to the commercially available forms of the drug.
Eiffel has supplied re-engineered insulin to companies for use in either oral or transdermal delivery. These companies will be testing Eiffel's product in different delivery devices.
“We must prioritise our insulin research to areas where the technology has the potential to add maximal commercial and shareholder value“, said Eiffel’s Managing Director and CEO, Christine Cussen. “The potential opportunities for inhaled and oral insulin are large and we want to capitalise on these opportunities.”
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
High folic acid in pregnancy could cause early bleeding
Women taking at least 800 micrograms of folic acid daily were more likely to report spotting and...
